STAAR Surgical CompanySTAA stock score: 53/100
$25.03 · -1.26% · Scored Nov 19, 2026
- Technical
- 45
- Fundamental
- 55
- News
- —
The reading
STAAR Surgical Company (STAA) scores 53 out of 100, which reads neutral, higher than 57% of Healthcare stocks and 54% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 55, technicals 45.
Among the fundamentals, Earnings Growth (Quarterly) at 100 and Current Ratio at 99 score highest, while Earnings Quality (Yearly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 51 and contrarian oscillators 48.
Since Aug 22, 2026 the composite has ranged from 35 to 54, and it is up 14 points over the period.
About STAAR Surgical Company
STAAR Surgical (STAA) is a medical device company based in California that makes implantable lenses for vision correction. Its main product line is the EVO family of Implantable Collamer Lenses, which a surgeon places inside the eye in front of the natural lens to correct nearsightedness, with or without astigmatism, as an alternative to laser surgery such as LASIK. The lenses are made of Collamer, a material developed by the company, and can be removed if needed. STAAR sells in many countries, with China its largest market, and reaches surgeons and clinics through a mix of direct sales teams and independent distributors. It earns money from sales of lenses and related products, and it remains an independent public company after its shareholders rejected a proposed acquisition by Alcon.
STAAR competes mainly with laser vision correction procedures, which use equipment from Zeiss, Alcon, Johnson & Johnson Vision and Bausch + Lomb, as well as with other lens makers. Its edge rests on a lens that preserves the cornea, a long clinical record and strong recognition among refractive surgeons in Asia. Investors who follow STAA stock tend to watch sales in China and inventory held by its distributors there. Adoption in the United States and other markets is closely followed. Gross margins, operating costs, tariffs and the views of its large shareholders are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward STAA’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
55Pulling it up
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Current assets divided by current liabilities: the ability to pay short-term bills.
Year-over-year revenue growth for each of the last four quarters, weighted toward the latest.
Holding it back
How reliably yearly earnings grow: the share of years with higher earnings, the compound growth rate, how steady that growth is, and the last two yearly changes.
5-year earnings growth evaluates long-term profit trajectory and consistency.
Trailing P/E ratio uses the last 12 months of actual earnings.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
54Pulling it up
Performance versus SPY compares the stock's returns to the S&P 500 index.
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Holding it back
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
SPY SMA 20 measures the S&P 500 (SPY) position relative to its 20-period moving average.
SPY SMA 50 tracks the S&P 500 (SPY) position relative to its 50-period moving average.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 33 | 1 |
| Daily | 54 | 3 |
| Weekly | 47 | 2 |
| Monthly | 40 | 2 |
| Quarterly | 42 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 53 |
| Nov 18, 2026 | 53 |
| Nov 17, 2026 | 53 |
| Nov 16, 2026 | 54 |
| Nov 15, 2026 | 54 |
| Nov 14, 2026 | 54 |
| Nov 13, 2026 | 54 |
| Nov 12, 2026 | 54 |
| Nov 11, 2026 | 46 |
| Nov 10, 2026 | 41 |
| Nov 8, 2026 | 44 |
| Nov 7, 2026 | 44 |
| Nov 6, 2026 | 44 |
| Nov 5, 2026 | 47 |
| Nov 4, 2026 | 48 |
| Nov 3, 2026 | 46 |
| Nov 2, 2026 | 46 |
| Nov 1, 2026 | 45 |
| Oct 30, 2026 | 45 |
| Oct 29, 2026 | 46 |
| Oct 28, 2026 | 46 |
| Oct 27, 2026 | 45 |
| Oct 26, 2026 | 42 |
| Oct 25, 2026 | 42 |
| Oct 24, 2026 | 42 |
| Oct 23, 2026 | 41 |
| Oct 22, 2026 | 41 |
| Oct 21, 2026 | 39 |
| Oct 20, 2026 | 40 |
| Oct 19, 2026 | 39 |
| Oct 18, 2026 | 38 |
| Oct 17, 2026 | 38 |
| Oct 16, 2026 | 37 |
| Oct 15, 2026 | 41 |
| Oct 14, 2026 | 38 |
| Oct 13, 2026 | 37 |
| Oct 12, 2026 | 38 |
| Oct 11, 2026 | 39 |
| Oct 10, 2026 | 38 |
| Oct 9, 2026 | 38 |
| Oct 8, 2026 | 38 |
| Oct 7, 2026 | 40 |
| Oct 6, 2026 | 39 |
| Oct 5, 2026 | 41 |
| Oct 4, 2026 | 40 |
| Oct 3, 2026 | 40 |
| Oct 2, 2026 | 40 |
| Oct 1, 2026 | 39 |
| Sep 30, 2026 | 40 |
| Sep 29, 2026 | 40 |
| Sep 28, 2026 | 37 |
| Sep 27, 2026 | 37 |
| Sep 26, 2026 | 37 |
| Sep 25, 2026 | 37 |
| Sep 24, 2026 | 37 |
| Sep 23, 2026 | 36 |
| Sep 22, 2026 | 37 |
| Sep 21, 2026 | 35 |
| Sep 20, 2026 | 36 |
| Sep 19, 2026 | 36 |
| Sep 18, 2026 | 35 |
| Sep 17, 2026 | 36 |
| Sep 16, 2026 | 38 |
| Sep 15, 2026 | 37 |
| Sep 14, 2026 | 39 |
| Sep 13, 2026 | 38 |
| Sep 12, 2026 | 38 |
| Sep 11, 2026 | 38 |
| Sep 10, 2026 | 39 |
| Sep 9, 2026 | 40 |
| Sep 8, 2026 | 41 |
| Sep 7, 2026 | 40 |
| Sep 6, 2026 | 41 |
| Sep 5, 2026 | 41 |
| Sep 4, 2026 | 41 |
| Sep 3, 2026 | 50 |
| Sep 2, 2026 | 40 |
| Sep 1, 2026 | 41 |
| Aug 31, 2026 | 39 |
| Aug 30, 2026 | 37 |
| Aug 29, 2026 | 37 |
| Aug 28, 2026 | 37 |
| Aug 27, 2026 | 37 |
| Aug 26, 2026 | 38 |
| Aug 25, 2026 | 39 |
| Aug 24, 2026 | 40 |
| Aug 23, 2026 | 39 |
| Aug 22, 2026 | 39 |
Key facts
- Market cap
- $1.3B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Beta
- 1.20
- Risk grade (1–10)
- 6
- Next earnings
- Nov 4, 2026
Medical Instruments & Supplies peers
| Company | Market cap | Score |
|---|---|---|
| WRBY Warby Parker | $3.0B | 59 |
| ATRC AtriCure | $2.8B | 58 |
| AZTA Azenta | $2.0B | 49 |
| LMAT LeMaitre Vascular | $1.7B | 65 |
| XRAY DENTSPLY SIRONA | $1.7B | 46 |
| KMTS Kestra Medical Technologies | $1.6B | 50 |
All Medical Instruments & Supplies stocks, highest-scored first
Questions
What is STAA's stock rating today?
STAA scores 53/100 (Neutral) as of Nov 19, 2026: technical 45, fundamental 55. Scores are recomputed every night.
What does STAAR Surgical Company do?
STAAR Surgical (STAA) is a medical device company based in California that makes implantable lenses for vision correction. Its main product line is the EVO family of Implantable Collamer Lenses, which a surgeon places inside the eye in front of the natural lens to correct nearsightedness, with or without astigmatism, as an alternative to laser surgery such as LASIK.
Is STAA stock a buy?
The score is not a buy or sell recommendation. A 53 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the STAA score calculated?
100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/staa/"><img src="https://stocksscores.com/stocks/staa/badge.svg" alt="STAA stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/staa/)